Subramanian Venkataraman, MD
Gastroenterology · Oak Lawn, ILNPI 1154347748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,051 of the $1,283 with a category attached, or 81.9%. 15 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 24.6% of the total. 2025 is the largest year on record at $450, 3.1 times the $145 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in IL, where the typical reported total is $1,251.
Across 48 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$316
- Madrigal Pharmaceuticals$226
- Braintree Laboratories, Inc.$202
- AbbVie$106
- Boston Scientific$105
- Ardelyx, Inc.$47
- plus $281 from 9 others
What the payments were for
- Food & beverage$1,05182%
- Education$323%
- Gifts$19916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $316 |
| Madrigal Pharmaceuticals | 6 | $226 |
| Braintree Laboratories, Inc. | 4 | $202 |
| AbbVie | 2 | $106 |
| Boston Scientific | 2 | $105 |
| Ardelyx, Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Intuitive Surgical | 1 | $41 |
| Redhill Biopharma Inc. | 1 | $39 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Pfizer | 2 | $33 |
| Novo Nordisk | 1 | $32 |
| Bristol Myers Squibb | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Echosens North America, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$126
How this compares
$1,283 in reported general payments places this provider in the 50th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $39,444 |
| LinzessLinaclotide | 19 | $15,009 |
| OzempicSemaglutide | 11 | $10,320 |
| EliquisApixaban | 13 | $7,369 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 235 | $5,313 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 68 | $4,413 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 27 | $1,983 |
| Lactulose | 57 | $1,936 |
| Mercaptopurine | 12 | $1,285 |
| Simvastatin | 113 | $1,245 |
| Febuxostat | 14 | $1,235 |
| Nebivolol Hcl | 20 | $1,205 |
| Famotidine | 67 | $1,148 |
| Lidocaine | 12 | $1,058 |
| Omeprazole | 110 | $964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $43 | $39,44412 claims |
| AbbVieLinzess | $106 | $15,00919 claims |
| Novo NordiskOzempic | $32 | $10,32011 claims |
| PfizerEliquis | $33 | $7,36913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Oak Lawn
- Rogelio SilvaOak Lawn$402K
- Kamran AyubOak Lawn$266K
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Amar NaikDes Plaines$1.2M
- Darren BrennerChicago$1.1M
- Jonathan RosenbergGurnee$1M
- Daksesh PatelEvanston$745K
- Russell CohenChicago$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.